Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

MorphoSys Teams Up Again With Novartis For Preclinical Cancer Program

Gets $23m Upfront Fee

Dec 07 2022

• By Kevin Grogan

MorphoSys — • Source: MorphoSys

Related Content

MorphoSys Hits Refresh Button On Pipeline With Constellation Buy

Jun 02 2021

MorphoSys Upbeat Despite Partner Failures In Alzheimer's And Rheumatoid Arthritis

Nov 18 2022

MorphoSys Takes $252.1m Impairment Charge As It Slims Down R&D

Mar 11 2022

Related Companies

MorphoSys AG

Constellation Pharmaceuticals, Inc.

Novartis AG

Royalty Pharma plc

Versanis Bio

Incyte Corporation

Additional Topics

Deals Strategy Commercial Cancer BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window